One month after an FDA advisory panel unanimously turned thumbs down on Abbott Laboratory's experimental therapy for prostate cancer, the agency officially concurred with a "not approvable" letter. Undeterred, Abbott said that it would continue with a Phase III trial of Xinlay in 1,000 men whose cancer had yet to spread. Abbott believes that the therapy could prove effective in early-stages of the disease. Two early trials failed to hit their primary endpoints.
- read this report from WebIndia for more